Can fluconazole (antifungal medication) and metronidazole (antibacterial and antiprotozoal medication) be administered together in a patient with a fungal infection and a bacterial or protozoal infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Fluconazole and Metronidazole Be Given Together?

Yes, fluconazole and metronidazole can be safely co-administered together, as there are no documented drug-drug interactions between these medications, and this combination is clinically appropriate when treating mixed anaerobic-fungal infections. 1

Safety Profile of Co-Administration

  • No pharmacokinetic interactions exist between metronidazole and fluconazole, as fluconazole's CYP450 interactions do not significantly affect metronidazole metabolism 1
  • Fluconazole has been studied extensively for drug interactions with other medications, and while potential interactions are common in hospitalized patients (occurring in 70% of admissions), clinically significant adverse events from fluconazole drug interactions are rare 2
  • Metronidazole is metabolized primarily by the liver to 5 metabolites and has low protein binding (<20%), making it less susceptible to displacement interactions 3

Clinical Scenarios Requiring Both Medications

Mixed anaerobic-fungal infections are the primary indication for combining these agents:

  • In critically ill patients with intra-abdominal sepsis, both anaerobes and Candida species may be present, requiring metronidazole for anaerobic coverage and fluconazole for fungal coverage 1
  • The IDSA recommends empiric antifungal therapy in critically ill patients with risk factors for invasive candidiasis, which frequently overlap with anaerobic infection risk factors 1

Dosing Recommendations When Using Both Agents

For mixed anaerobic-fungal infections:

  • Start metronidazole 500 mg IV/PO every 8 hours for anaerobic coverage 1
  • Add fluconazole 800 mg loading dose on Day 1, then 400 mg daily for empiric Candida coverage 4, 1

For sequential therapy (when candidiasis develops during metronidazole treatment):

  • Add fluconazole 150 mg single dose for uncomplicated vulvovaginal candidiasis 1
  • Use fluconazole 400 mg daily for more severe or invasive infections 1

High-Risk Populations Requiring Dual Coverage

Consider empiric coverage for both anaerobes and Candida in ICU patients with multiple risk factors including:

  • Recent abdominal or bowel surgery 1
  • Prolonged broad-spectrum antibiotic use 1
  • Central venous catheters 1
  • Parenteral nutrition 1
  • Dialysis 4

Important Caveats

Pregnancy considerations:

  • Metronidazole is acceptable for anaerobic infections in pregnant women 1
  • Fluconazole should be used cautiously in pregnancy, with amphotericin B deoxycholate preferred for invasive candidiasis 1

Duration of therapy:

  • Fluconazole should be continued for 14 days after the first negative blood culture for candidemia 1
  • Metronidazole duration depends on the specific anaerobic infection being treated 3, 5

Monitoring:

  • Both medications can cause elevation of liver enzymes, though this rarely requires treatment modification 6
  • No specific additional monitoring is required when these drugs are used together beyond standard monitoring for each individual agent 1

References

Guideline

Metronidazole and Fluconazole Co-Prescription Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Efficacy of fluconazole in the treatment of systemic fungal infections.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1992

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.